Boston Scientific Corp (BSX) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Boston Scientific Corp (BSX)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

48.55

-0.30 (0.61%)

as of Jun 5, 2026, 8:00:00 pm Market Open.

100 watching

Investor Insights

Jun 5, 2026, 12:00 am

This summary was created by AI, based on 8 opinions in the last 12 months.

Boston Scientific Corp (BSX) has garnered mixed reviews from experts, reflecting a range of perspectives on its investment potential. While it is recognized as a leader in the medical device industry with products in cardiology and endoscopy, analysts caution that the stock has faced significant challenges over the past year, including slowing organic growth and increased competition from rivals like Medtronic, Abbott, and Johnson & Johnson. The recent market performance has led to concerns about its high valuation, with some experts recommending a wait-and-see approach rather than aggressive investment. Others, however, argue that despite the near-term weakness, the company is well-managed and poised for long-term growth, driven by an aging population and demand for less invasive devices. Overall, while the stock appears attractive at the current price, caution is advised given the current market dynamics and valuation metrics.

Consensus

Mixed

Valuation

Overvalued

Similar

Medtronic,MDT

BUY

Things look good for them. Won a patent case against Johnson & Johnson (JNJ-N).

WEAK BUY

It's close to a buy. Model price is $32.09 which is a 5% differential.

TOP PICK

"We really like Boston [Scientific]" Thinks they have a better product then the competitor. Had a series of recalls, but have been able to gain back the marketshare. But the stock didn't recover as well. So is now undervalued.

DON'T BUY

Long term chart shows that it made a base, had a fantastic rise to $45 in 2002/2003, very little top formation and now we are in a downtrend. Stock has now fallen below its 200 day moving average.

BUY

A good company. Their coated stents is a terrific product. Up against Johnson & Johnson in the stent business, but they are holding their own. A good buy at this price.

WEAK BUY

Stock has dropped because of the recall of their stent. Price is reasonably attractive.

TOP PICK

A company that focuses on earnings. A tremendous new product that should give a nice boost to their income.

DON'T BUY

Its drug coated stent is driving the price up, but other competitors are lurking on the horizon. Not cheap.

TOP PICK

Likes this sector. Strong and persistant growth. Revenue and earnings growth has been very persistant. Good products. Buy on pull backs.

Showing 61 to 69 of 69 entries

Most Recent Experts

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Virtus Investment Partners

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Boston Scientific Corp (BSX)